HYDERABAD: City-based biotechnology startup PopVax is developing AI-designed personalised cancer vaccines using messenger RNA ...

Hyderabad startup PopVax develops personalised cancer vaccines using AI, machine learning, and mRNA tech to target unique tumour mutations.

PopVax’s new facility aims to design and manufacture mRNA doses tailored to the genetic mutations of a single patient’s ...

Moderna (NasdaqGS:MRNA) faces fresh regulatory questions as prediction markets start trading on FDA timelines for its ...

Helen Branswell covered issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Health secretary Robert F. Kennedy Jr. on Tuesday announced ...

Denise Fitzsimmons knew that removing the fast-growing lump above her eyebrow in 2024 didn’t eliminate the possibility that her melanoma could return. But a clinical trial at Penn Medicine offered the ...

Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA ...

RNA speeds the design process By combining multiple antigens within a divergent vaccine, researchers can boost populations of B cells that recognize the conserved areas of multiple variants. This is ...

In a head-to-head mouse study, an adenoviral RSV vaccine built stronger systemic immunity while a self-amplifying RNA vaccine ...

Hyderabad-based PopVax unveils RNA Foundry to produce personalised mRNA cancer vaccines for patients.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Allison covers what hot startups are getting up to, and who’s financing them. She ...

RNA medicines can reduce the production of proteins involved in disease by acting on the messages cells use to make them. Their development has produced treatments for inherited nerve disorders, ...